ID   TREX1_HUMAN             Reviewed;         369 AA.
AC   Q9NSU2; B2RCN9; Q8TEU2; Q9BPW1; Q9Y4X2;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=Three-prime repair exonuclease 1;
DE            EC=3.1.11.2;
DE   AltName: Full=3'-5' exonuclease TREX1;
DE   AltName: Full=DNase III;
GN   Name=TREX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=10393201; DOI=10.1093/emboj/18.13.3868;
RA   Hoess M., Robins P., Naven T.J.P., Pappin D.J.C., Sgouros J.,
RA   Lindahl T.;
RT   "A human DNA editing enzyme homologous to the Escherichia coli
RT   DnaQ/MutD protein.";
RL   EMBO J. 18:3868-3875(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), AND FUNCTION.
RX   PubMed=10391904; DOI=10.1074/jbc.274.28.19655;
RA   Mazur D.J., Perrino F.W.;
RT   "Identification and expression of the TREX1 and TREX2 cDNA sequences
RT   encoding mammalian 3'-->5' exonucleases.";
RL   J. Biol. Chem. 274:19655-19660(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11278605; DOI=10.1074/jbc.M010051200;
RA   Mazur D.J., Perrino F.W.;
RT   "Structure and expression of the TREX1 and TREX2 3'-->5' exonuclease
RT   genes.";
RL   J. Biol. Chem. 276:14718-14727(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN CELL DEATH, IDENTIFICATION IN THE SET COMPLEX, INTERACTION
RP   WITH NME1 AND SET, AND SUBCELLULAR LOCATION.
RX   PubMed=16818237; DOI=10.1016/j.molcel.2006.06.005;
RA   Chowdhury D., Beresford P.J., Zhu P., Zhang D., Sung J.S., Demple B.,
RA   Perrino F.W., Lieberman J.;
RT   "The exonuclease TREX1 is in the SET complex and acts in concert with
RT   NM23-H1 to degrade DNA during granzyme A-mediated cell death.";
RL   Mol. Cell 23:133-142(2006).
RN   [9]
RP   FUNCTION IN CELL CYCLE REGULATION, AND CHARACTERIZATION OF VARIANT
RP   AGS1 HIS-169.
RX   PubMed=18045533; DOI=10.1016/j.cell.2007.10.017;
RA   Yang Y.G., Lindahl T., Barnes D.E.;
RT   "Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint
RT   activation and autoimmune disease.";
RL   Cell 131:873-886(2007).
RN   [10]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS AGS1 HIS-169; ASP-255 INS
RP   AND ASP-256.
RX   PubMed=17293595; DOI=10.1074/jbc.M700039200;
RA   de Silva U., Choudhury S., Bailey S.L., Harvey S., Perrino F.W.,
RA   Hollis T.;
RT   "The crystal structure of TREX1 explains the 3' nucleotide specificity
RT   and reveals a polyproline II helix for protein partnering.";
RL   J. Biol. Chem. 282:10537-10543(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-133 AND SER-316, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION IN OXIDIZED DNA DEGRADATION, AND POTENTIAL ROLE IN SLE SKIN
RP   LESIONS.
RX   PubMed=23993650; DOI=10.1016/j.immuni.2013.08.004;
RA   Gehrke N., Mertens C., Zillinger T., Wenzel J., Bald T., Zahn S.,
RA   Tueting T., Hartmann G., Barchet W.;
RT   "Oxidative damage of DNA confers resistance to cytosolic nuclease
RT   TREX1 degradation and potentiates STING-dependent immune sensing.";
RL   Immunity 39:482-495(2013).
RN   [13]
RP   INTERACTION WITH UBQLN1, UBIQUITINATION, CHARACTERIZATION OF VARIANTS
RP   AGS1 ALA-177; LYS-253; ASN-255 AND PRO-358, CHARACTERIZATION OF
RP   VARIANTS SLE LEU-345 AND CYS-360, AND MUTAGENESIS OF LYS-85; LYS-121;
RP   LYS-130; LYS-215; LYS-230; LYS-297; LYS-326 AND LYS-332.
RX   PubMed=23979357; DOI=10.1074/jbc.M113.503391;
RA   Orebaugh C.D., Fye J.M., Harvey S., Hollis T., Wilkinson J.C.,
RA   Perrino F.W.;
RT   "The TREX1 C-terminal region controls cellular localization through
RT   ubiquitination.";
RL   J. Biol. Chem. 288:28881-28892(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   VARIANTS AGS1 HIS-169; ASP-255 INS AND ASP-256.
RX   PubMed=16845398; DOI=10.1038/ng1845;
RA   Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M.,
RA   Black D.N., van Bokhoven H., Brunner H.G., Hamel B.C.J., Corry P.C.,
RA   Cowan F.M., Frints S.G., Klepper J., Livingston J.H., Lynch S.A.,
RA   Massey R.F., Meritet J.F., Michaud J.L., Ponsot G., Voit T., Lebon P.,
RA   Bonthron D.T., Jackson A.P., Barnes D.E., Lindahl T.;
RT   "Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause
RT   Aicardi-Goutieres syndrome at the AGS1 locus.";
RL   Nat. Genet. 38:917-920(2006).
RN   [18]
RP   INVOLVEMENT IN CHBL1, VARIANT AGS1 ASN-255, AND CHARACTERIZATION OF
RP   VARIANT AGS1 ASN-255.
RX   PubMed=17357087; DOI=10.1086/513443;
RA   Rice G., Newman W.G., Dean J., Patrick T., Parmar R., Flintoff K.,
RA   Robins P., Harvey S., Hollis T., O'Hara A., Herrick A.L., Bowden A.P.,
RA   Perrino F.W., Lindahl T., Barnes D.E., Crow Y.J.;
RT   "Heterozygous mutations in TREX1 cause familial chilblain lupus and
RT   dominant Aicardi-Goutieres syndrome.";
RL   Am. J. Hum. Genet. 80:811-815(2007).
RN   [19]
RP   VARIANTS AGS1 HIS-169; ALA-177; ASN-255; ASP-256 AND PRO-358.
RX   PubMed=17846997; DOI=10.1086/521373;
RA   Rice G., Patrick T., Parmar R., Taylor C.F., Aeby A., Aicardi J.,
RA   Artuch R., Montalto S.A., Bacino C.A., Barroso B., Baxter P.,
RA   Benko W.S., Bergmann C., Bertini E., Biancheri R., Blair E.M.,
RA   Blau N., Bonthron D.T., Briggs T., Brueton L.A., Brunner H.G.,
RA   Burke C.J., Carr I.M., Carvalho D.R., Chandler K.E., Christen H.J.,
RA   Corry P.C., Cowan F.M., Cox H., D'Arrigo S., Dean J., De Laet C.,
RA   De Praeter C., Dery C., Ferrie C.D., Flintoff K., Frints S.G.,
RA   Garcia-Cazorla A., Gener B., Goizet C., Goutieres F., Green A.J.,
RA   Guet A., Hamel B.C., Hayward B.E., Heiberg A., Hennekam R.C.,
RA   Husson M., Jackson A.P., Jayatunga R., Jiang Y.H., Kant S.G., Kao A.,
RA   King M.D., Kingston H.M., Klepper J., van der Knaap M.S.,
RA   Kornberg A.J., Kotzot D., Kratzer W., Lacombe D., Lagae L.,
RA   Landrieu P.G., Lanzi G., Leitch A., Lim M.J., Livingston J.H.,
RA   Lourenco C.M., Lyall E.G., Lynch S.A., Lyons M.J., Marom D.,
RA   McClure J.P., McWilliam R., Melancon S.B., Mewasingh L.D.,
RA   Moutard M.L., Nischal K.K., Ostergaard J.R., Prendiville J.,
RA   Rasmussen M., Rogers R.C., Roland D., Rosser E.M., Rostasy K.,
RA   Roubertie A., Sanchis A., Schiffmann R., Scholl-Burgi S., Seal S.,
RA   Shalev S.A., Corcoles C.S., Sinha G.P., Soler D., Spiegel R.,
RA   Stephenson J.B., Tacke U., Tan T.Y., Till M., Tolmie J.L., Tomlin P.,
RA   Vagnarelli F., Valente E.M., Van Coster R.N., Van der Aa N.,
RA   Vanderver A., Vles J.S., Voit T., Wassmer E., Weschke B.,
RA   Whiteford M.L., Willemsen M.A., Zankl A., Zuberi S.M., Orcesi S.,
RA   Fazzi E., Lebon P., Crow Y.J.;
RT   "Clinical and molecular phenotype of Aicardi-Goutieres syndrome.";
RL   Am. J. Hum. Genet. 81:713-725(2007).
RN   [20]
RP   VARIANT CHBL1 ASN-73, AND CHARACTERIZATION OF VARIANT CHBL1 ASN-73.
RX   PubMed=17440703; DOI=10.1007/s00109-007-0199-9;
RA   Lee-Kirsch M.A., Chowdhury D., Harvey S., Gong M., Senenko L.,
RA   Engel K., Pfeiffer C., Hollis T., Gahr M., Perrino F.W., Lieberman J.,
RA   Hubner N.;
RT   "A mutation in TREX1 that impairs susceptibility to granzyme A-
RT   mediated cell death underlies familial chilblain lupus.";
RL   J. Mol. Med. 85:531-537(2007).
RN   [21]
RP   VARIANTS SLE HIS-169; VAL-213; SER-282; SER-295; PRO-302; LEU-345;
RP   CYS-360 AND ALA-361, AND VARIANT GLY-321.
RX   PubMed=17660818; DOI=10.1038/ng2091;
RA   Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K.,
RA   Lee Y.A., de Silva U., Bailey S.L., Witte T., Vyse T.J., Kere J.,
RA   Pfeiffer C., Harvey S., Wong A., Koskenmies S., Hummel O., Rohde K.,
RA   Schmidt R.E., Dominiczak A.F., Gahr M., Hollis T., Perrino F.W.,
RA   Lieberman J., Huebner N.;
RT   "Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are
RT   associated with systemic lupus erythematosus.";
RL   Nat. Genet. 39:1065-1067(2007).
RN   [22]
RP   INVOLVEMENT IN RVCL.
RX   PubMed=17660820; DOI=10.1038/ng2082;
RA   Richards A., van den Maagdenberg A.M.J.M., Jen J.C., Kavanagh D.,
RA   Bertram P., Spitzer D., Liszewski M.K., Barilla-Labarca M.-L.,
RA   Terwindt G.M., Kasai Y., McLellan M., Grand M.G., Vanmolkot K.R.J.,
RA   de Vries B., Wan J., Kane M.J., Mamsa H., Schaefer R., Stam A.H.,
RA   Haan J., de Jong P.T.V.M., Storimans C.W., van Schooneveld M.J.,
RA   Oosterhuis J.A., Gschwendter A., Dichgans M., Kotschet K.E.,
RA   Hodgkinson S., Hardy T.A., Delatycki M.B., Hajj-Ali R.A.,
RA   Kothari P.H., Nelson S.F., Frants R.R., Baloh R.W., Ferrari M.D.,
RA   Atkinson J.P.;
RT   "C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause
RT   autosomal dominant retinal vasculopathy with cerebral
RT   leukodystrophy.";
RL   Nat. Genet. 39:1068-1070(2007).
RN   [23]
RP   VARIANT AGS1 ASN-73.
RX   PubMed=20799324; DOI=10.1002/ajmg.a.33620;
RA   Haaxma C.A., Crow Y.J., van Steensel M.A., Lammens M.M., Rice G.I.,
RA   Verbeek M.M., Willemsen M.A.;
RT   "A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-
RT   Goutieres syndrome.";
RL   Am. J. Med. Genet. A 152:2612-2617(2010).
RN   [24]
RP   VARIANTS AGS1 HIS-169; LYS-253 AND HIS-255, AND VARIANT SLE HIS-255.
RX   PubMed=20131292; DOI=10.1002/art.27367;
RA   Ramantani G., Kohlhase J., Hertzberg C., Innes A.M., Engel K.,
RA   Hunger S., Borozdin W., Mah J.K., Ungerath K., Walkenhorst H.,
RA   Richardt H.H., Buckard J., Bevot A., Siegel C., von Stuelpnagel C.,
RA   Ikonomidou C., Thomas K., Proud V., Niemann F., Wieczorek D.,
RA   Haeusler M., Niggemann P., Baltaci V., Conrad K., Lebon P.,
RA   Lee-Kirsch M.A.;
RT   "Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-
RT   Goutieres syndrome.";
RL   Arthritis Rheum. 62:1469-1477(2010).
CC   -!- FUNCTION: Major cellular 3'-to-5' DNA exonuclease which digests
CC       single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with
CC       mismatched 3' termini. Prevents cell-intrinsic initiation of
CC       autoimmunity. Acts by metabolizing DNA fragments from endogenous
CC       retroelements, including L1, LTR and SINE elements. Unless
CC       degraded, these DNA fragments accumulate in the cytosol and
CC       activate the IFN-stimulatory DNA (ISD) response and innate immune
CC       signaling. Prevents chronic ATM-dependent checkpoint activation,
CC       by processing ssDNA polynucleotide species arising from the
CC       processing of aberrant DNA replication intermediates.
CC       Inefficiently degrades oxidized DNA, such as that generated upon
CC       antimicrobial reactive oxygen production or upon absorption of UV
CC       light. During GZMA-mediated cell death, contributes to DNA damage
CC       in concert with NME1. NME1 nicks one strand of DNA and TREX1
CC       removes bases from the free 3' end to enhance DNA damage and
CC       prevent DNA end reannealing and rapid repair.
CC       {ECO:0000269|PubMed:10391904, ECO:0000269|PubMed:10393201,
CC       ECO:0000269|PubMed:16818237, ECO:0000269|PubMed:17293595,
CC       ECO:0000269|PubMed:18045533, ECO:0000269|PubMed:23993650}.
CC   -!- CATALYTIC ACTIVITY: Exonucleolytic cleavage in the 3'- to 5'-
CC       direction to yield nucleoside 5'-phosphates.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 Mg(2+) per subunit. The second magnesium ion
CC       interacts with only one residue. Substitution with Mn(2+) results
CC       in partial activity. {ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Interacts (via proline-rich region) with
CC       TCERG1/CA150 (via the second WW domain). Component of the SET
CC       complex, composed of at least ANP32A, APEX1, HMGB2, NME1, SET and
CC       TREX1. Within this complex, directly interacts with SET; this
CC       interaction does not result in TREX1 inhibition. Also interacts
CC       with NME1, but only following translocation to the nucleus.
CC       Directly interacts with UBQLN1 (via ubiquitin-like domain); the
CC       interaction may control TREX1 subcellular location.
CC       {ECO:0000269|PubMed:16818237, ECO:0000269|PubMed:23979357}.
CC   -!- INTERACTION:
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-10313481, EBI-10172290;
CC       P60409-2:KRTAP10-7; NbExp=3; IntAct=EBI-10313481, EBI-10695388;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, cytosol. Endoplasmic
CC       reticulum membrane; Peripheral membrane protein. Note=Retained in
CC       the cytoplasm through the C-terminal region (By similarity). In
CC       response to DNA damage, translocates to the nucleus where it is
CC       specifically recruited to replication foci. Translocation to the
CC       nucleus also occurs during GZMA-mediated cell death.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NSU2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NSU2-2; Sequence=VSP_010445;
CC       Name=3;
CC         IsoId=Q9NSU2-3; Sequence=VSP_010446;
CC   -!- TISSUE SPECIFICITY: Detected in thymus, spleen, liver, brain,
CC       heart, small intestine and colon. {ECO:0000269|PubMed:10393201,
CC       ECO:0000269|PubMed:11278605}.
CC   -!- INDUCTION: Induced by cytosolic DNA. Induced by inflammatory
CC       stimuli such as IFN-alpha and IFN-gamma in B cells and also by LPS
CC       and viral and bacterial DNA (via TLR9) in dendritic cells and
CC       macrophages (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated, but not targeted to proteasomal degradation.
CC       Ubiquitination may be important for interaction with UBQLN1.
CC       {ECO:0000269|PubMed:23979357}.
CC   -!- DISEASE: Aicardi-Goutieres syndrome 1 (AGS1) [MIM:225750]: A form
CC       of Aicardi-Goutieres syndrome, a genetically heterogeneous disease
CC       characterized by cerebral atrophy, leukoencephalopathy,
CC       intracranial calcifications, chronic cerebrospinal fluid (CSF)
CC       lymphocytosis, increased CSF alpha-interferon, and negative
CC       serologic investigations for common prenatal infection. Clinical
CC       features as thrombocytopenia, hepatosplenomegaly and elevated
CC       hepatic transaminases along with intermittent fever may
CC       erroneously suggest an infective process. Severe neurological
CC       dysfunctions manifest in infancy as progressive microcephaly,
CC       spasticity, dystonic posturing and profound psychomotor
CC       retardation. Death often occurs in early childhood.
CC       {ECO:0000269|PubMed:16845398, ECO:0000269|PubMed:17293595,
CC       ECO:0000269|PubMed:17357087, ECO:0000269|PubMed:17846997,
CC       ECO:0000269|PubMed:18045533, ECO:0000269|PubMed:20131292,
CC       ECO:0000269|PubMed:20799324, ECO:0000269|PubMed:23979357}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A
CC       chronic, relapsing, inflammatory, and often febrile multisystemic
CC       disorder of connective tissue, characterized principally by
CC       involvement of the skin, joints, kidneys and serosal membranes. It
CC       is of unknown etiology, but is thought to represent a failure of
CC       the regulatory mechanisms of the autoimmune system. The disease is
CC       marked by a wide range of system dysfunctions, an elevated
CC       erythrocyte sedimentation rate, and the formation of LE cells in
CC       the blood or bone marrow. {ECO:0000269|PubMed:17660818,
CC       ECO:0000269|PubMed:20131292, ECO:0000269|PubMed:23979357}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. Enhanced immune
CC       sensing of oxidized DNA may be involved in the phototoxicity
CC       experienced by SLE patients. Exposure to UV-light produces DNA
CC       oxidative damage. Oxidized DNA being a poor TREX1 substrate, it
CC       accumulates in skin, leading to enhanced auto-immune reactivity
CC       and eventually skin lesions (PubMed:23993650).
CC       {ECO:0000269|PubMed:23993650}.
CC   -!- DISEASE: Chilblain lupus 1 (CHBL1) [MIM:610448]: A rare cutaneous
CC       form of lupus erythematosus. Affected individuals present with
CC       painful bluish-red papular or nodular lesions of the skin in acral
CC       locations precipitated by cold and wet exposure at temperatures
CC       less than 10 degrees centigrade. {ECO:0000269|PubMed:17357087,
CC       ECO:0000269|PubMed:17440703}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Vasculopathy, retinal, with cerebral leukodystrophy
CC       (RVCL) [MIM:192315]: A microvascular endotheliopathy resulting in
CC       central nervous system degeneration and retinopathy, with
CC       progressive loss of vision, stroke, motor impairment, and
CC       cognitive decline. The ocular manifestations are characterized by
CC       telangiectasias, microaneurysms and retinal capillary obliteration
CC       starting in the macula. Diseased cerebral white matter has
CC       prominent small infarcts that often coalesce to pseudotumors.
CC       {ECO:0000269|PubMed:17660820}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the exonuclease superfamily. TREX family.
CC       {ECO:0000305}.
CC   -!- CAUTION: The gene for this protein is either identical to or
CC       adjacent to that of ATRIP. Some of the mRNAs that encode ATRIP
CC       also encode TREX1 in another reading frame. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD48774.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/trex1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ243797; CAB50866.1; -; mRNA.
DR   EMBL; AF319566; AAK07613.1; -; mRNA.
DR   EMBL; AF319567; AAK07614.1; -; mRNA.
DR   EMBL; AF319568; AAK07615.1; -; mRNA.
DR   EMBL; AF319569; AAK07616.1; -; mRNA.
DR   EMBL; AF151105; AAD48774.2; ALT_INIT; mRNA.
DR   EMBL; AK315196; BAG37636.1; -; mRNA.
DR   EMBL; AL137745; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF483777; AAL82504.1; -; Genomic_DNA.
DR   EMBL; BC023630; AAH23630.1; -; mRNA.
DR   CCDS; CCDS2769.1; -. [Q9NSU2-3]
DR   CCDS; CCDS43086.1; -. [Q9NSU2-1]
DR   CCDS; CCDS59451.1; -. [Q9NSU2-2]
DR   PIR; T46299; T46299.
DR   RefSeq; NP_009179.2; NM_007248.3. [Q9NSU2-2]
DR   RefSeq; NP_057465.1; NM_016381.5. [Q9NSU2-1]
DR   RefSeq; NP_338599.1; NM_033629.4. [Q9NSU2-3]
DR   UniGene; Hs.707026; -.
DR   UniGene; Hs.713742; -.
DR   UniGene; Hs.744646; -.
DR   ProteinModelPortal; Q9NSU2; -.
DR   SMR; Q9NSU2; -.
DR   BioGrid; 116433; 11.
DR   IntAct; Q9NSU2; 5.
DR   MINT; MINT-1466830; -.
DR   STRING; 9606.ENSP00000390478; -.
DR   iPTMnet; Q9NSU2; -.
DR   PhosphoSitePlus; Q9NSU2; -.
DR   DMDM; 47606216; -.
DR   EPD; Q9NSU2; -.
DR   MaxQB; Q9NSU2; -.
DR   PaxDb; Q9NSU2; -.
DR   PeptideAtlas; Q9NSU2; -.
DR   PRIDE; Q9NSU2; -.
DR   DNASU; 11277; -.
DR   Ensembl; ENST00000444177; ENSP00000415972; ENSG00000213689. [Q9NSU2-2]
DR   Ensembl; ENST00000625293; ENSP00000486676; ENSG00000213689. [Q9NSU2-1]
DR   Ensembl; ENST00000629913; ENSP00000486444; ENSG00000213689. [Q9NSU2-3]
DR   GeneID; 11277; -.
DR   KEGG; hsa:11277; -.
DR   UCSC; uc031rzp.2; human. [Q9NSU2-1]
DR   CTD; 11277; -.
DR   DisGeNET; 11277; -.
DR   GeneCards; TREX1; -.
DR   GeneReviews; TREX1; -.
DR   HGNC; HGNC:12269; TREX1.
DR   HPA; HPA035437; -.
DR   MalaCards; TREX1; -.
DR   MIM; 152700; phenotype.
DR   MIM; 192315; phenotype.
DR   MIM; 225750; phenotype.
DR   MIM; 606609; gene.
DR   MIM; 610448; phenotype.
DR   neXtProt; NX_Q9NSU2; -.
DR   OpenTargets; ENSG00000213689; -.
DR   OpenTargets; ENSG00000282827; -.
DR   Orphanet; 51; Aicardi-Goutieres syndrome.
DR   Orphanet; 3421; Cerebroretinal vasculopathy.
DR   Orphanet; 90280; Chilblain lupus.
DR   Orphanet; 71291; Hereditary vascular retinopathy.
DR   Orphanet; 63261; HERNS syndrome.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   PharmGKB; PA36949; -.
DR   eggNOG; KOG4793; Eukaryota.
DR   eggNOG; ENOG4111YSP; LUCA.
DR   GeneTree; ENSGT00390000012715; -.
DR   GeneTree; ENSGT00390000012850; -.
DR   HOGENOM; HOG000118119; -.
DR   HOVERGEN; HBG079278; -.
DR   InParanoid; Q9NSU2; -.
DR   KO; K10790; -.
DR   OMA; LAVHRCA; -.
DR   OrthoDB; EOG091G0LSM; -.
DR   PhylomeDB; Q9NSU2; -.
DR   TreeFam; TF323333; -.
DR   Reactome; R-HSA-3248023; Regulation by TREX1.
DR   Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN.
DR   ChiTaRS; TREX1; human.
DR   GeneWiki; TREX1; -.
DR   GenomeRNAi; 11277; -.
DR   PRO; PR:Q9NSU2; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000213689; -.
DR   CleanEx; HS_TREX1; -.
DR   ExpressionAtlas; Q9NSU2; baseline.
DR   Genevisible; Q9NSU2; HS.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005635; C:nuclear envelope; NAS:UniProtKB.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0008296; F:3'-5'-exodeoxyribonuclease activity; ISS:UniProtKB.
DR   GO; GO:0008853; F:exodeoxyribonuclease III activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; TAS:UniProtKB.
DR   GO; GO:0032405; F:MutLalpha complex binding; IDA:MGI.
DR   GO; GO:0032407; F:MutSalpha complex binding; IDA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; TAS:UniProtKB.
DR   GO; GO:0006259; P:DNA metabolic process; ISS:UniProtKB.
DR   GO; GO:0006310; P:DNA recombination; NAS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006260; P:DNA replication; NAS:UniProtKB.
DR   GO; GO:0006298; P:mismatch repair; NAS:UniProtKB.
DR   GO; GO:0032479; P:regulation of type I interferon production; TAS:Reactome.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR013520; Exonuclease_RNaseT/DNA_pol3.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   SMART; SM00479; EXOIII; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
PE   1: Evidence at protein level;
KW   Aicardi-Goutieres syndrome; Alternative splicing; Complete proteome;
KW   Cytoplasm; Disease mutation; Endoplasmic reticulum; Exonuclease;
KW   Hydrolase; Magnesium; Membrane; Metal-binding; Neurodegeneration;
KW   Nuclease; Nucleus; Phosphoprotein; Reference proteome;
KW   Systemic lupus erythematosus; Ubl conjugation.
FT   CHAIN         1    369       Three-prime repair exonuclease 1.
FT                                /FTId=PRO_0000109868.
FT   REGION       75     76       Substrate binding. {ECO:0000250}.
FT   REGION      109    118       Proline-rich region. {ECO:0000250}.
FT   REGION      291    369       Necessary for endoplasmic reticulum
FT                                localization. {ECO:0000250}.
FT   REGION      298    369       Interaction with UBQLN1.
FT                                {ECO:0000269|PubMed:23979357}.
FT   REGION      336    369       Necessary for cytoplasmic retention.
FT                                {ECO:0000250}.
FT   ACT_SITE    250    250       Proton donor/acceptor. {ECO:0000250}.
FT   METAL        73     73       Magnesium 1. {ECO:0000250}.
FT   METAL        73     73       Magnesium 2. {ECO:0000250}.
FT   METAL        75     75       Magnesium 1. {ECO:0000250}.
FT   METAL       255    255       Magnesium 1. {ECO:0000250}.
FT   BINDING     184    184       Substrate. {ECO:0000250}.
FT   BINDING     255    255       Substrate. {ECO:0000250}.
FT   MOD_RES     133    133       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     222    222       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     316    316       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     65       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10393201}.
FT                                /FTId=VSP_010445.
FT   VAR_SEQ       1     55       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10391904}.
FT                                /FTId=VSP_010446.
FT   VARIANT      73     73       D -> N (in CHBL1 and AGS1; loss of
FT                                function; dbSNP:rs121908117).
FT                                {ECO:0000269|PubMed:17440703,
FT                                ECO:0000269|PubMed:20799324}.
FT                                /FTId=VAR_037948.
FT   VARIANT     169    169       R -> H (in AGS1 and SLE; primary
FT                                fibroblasts from an AGS1 patient carrying
FT                                H-169 show defective G1/S transition and
FT                                chronic G2/M DNA damage checkpoint
FT                                activation; strongly reduces activity;
FT                                dbSNP:rs72556554).
FT                                {ECO:0000269|PubMed:16845398,
FT                                ECO:0000269|PubMed:17293595,
FT                                ECO:0000269|PubMed:17660818,
FT                                ECO:0000269|PubMed:17846997,
FT                                ECO:0000269|PubMed:18045533,
FT                                ECO:0000269|PubMed:20131292}.
FT                                /FTId=VAR_028319.
FT   VARIANT     177    177       V -> A (in AGS1; increases ubiquitination
FT                                levels; no effect on exonuclease
FT                                activity; dbSNP:rs79993407).
FT                                {ECO:0000269|PubMed:17846997,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_070899.
FT   VARIANT     213    213       A -> V (in SLE; dbSNP:rs762011967).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037949.
FT   VARIANT     253    253       E -> K (in AGS1; increases ubiquitination
FT                                levels; no effect on exonuclease
FT                                activity). {ECO:0000269|PubMed:20131292,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_070900.
FT   VARIANT     255    255       D -> DD (in AGS1; heterozygous compound
FT                                with H-169; loss of activity).
FT                                {ECO:0000269|PubMed:16845398,
FT                                ECO:0000269|PubMed:17293595}.
FT                                /FTId=VAR_028320.
FT   VARIANT     255    255       D -> H (in AGS1 and SLE).
FT                                {ECO:0000269|PubMed:20131292}.
FT                                /FTId=VAR_070901.
FT   VARIANT     255    255       D -> N (in AGS1; autosomal dominant form;
FT                                no effect on dsDNA exonuclease activity;
FT                                abolishes ssDNA exonuclease activity;
FT                                dbSNP:rs78846775).
FT                                {ECO:0000269|PubMed:17357087,
FT                                ECO:0000269|PubMed:17846997,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_032940.
FT   VARIANT     256    256       V -> D (in AGS1; reduces activity by 75%;
FT                                dbSNP:rs78408272).
FT                                {ECO:0000269|PubMed:16845398,
FT                                ECO:0000269|PubMed:17293595,
FT                                ECO:0000269|PubMed:17846997}.
FT                                /FTId=VAR_028321.
FT   VARIANT     282    282       G -> S (in SLE; associated in cis with P-
FT                                302; dbSNP:rs113107733).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037950.
FT   VARIANT     295    295       R -> S (in SLE; dbSNP:rs72556555).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037951.
FT   VARIANT     302    302       A -> P (in SLE; associated in cis with S-
FT                                282; dbSNP:rs112741962).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037952.
FT   VARIANT     321    321       E -> G (in dbSNP:rs55999987).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037953.
FT   VARIANT     345    345       P -> L (in SLE; increases ubiquitination
FT                                levels; no effect on exonuclease
FT                                activity; dbSNP:rs148833270).
FT                                {ECO:0000269|PubMed:17660818,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_037954.
FT   VARIANT     358    358       T -> P (in AGS1; decreases ubiquitination
FT                                levels; decreases colocalization with
FT                                UBQLN1; no effect on exonuclease
FT                                activity; dbSNP:rs76224909).
FT                                {ECO:0000269|PubMed:17846997,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_070902.
FT   VARIANT     360    360       Y -> C (in SLE; decreases ubiquitination
FT                                levels; decreases colocalization with
FT                                UBQLN1; no effect on exonuclease
FT                                activity; dbSNP:rs370504038).
FT                                {ECO:0000269|PubMed:17660818,
FT                                ECO:0000269|PubMed:23979357}.
FT                                /FTId=VAR_037955.
FT   VARIANT     361    361       G -> A (in SLE; dbSNP:rs780022923).
FT                                {ECO:0000269|PubMed:17660818}.
FT                                /FTId=VAR_037956.
FT   MUTAGEN      85     85       K->R: Reduces ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     121    121       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     130    130       K->R: Reduces ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     215    215       K->R: Reduces ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     230    230       K->R: Reduces ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     297    297       K->R: Reduces ubiquitination.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     326    326       K->R: Reduces ubiquitination. Strongly
FT                                reduces ubiquitination; when associated
FT                                with R-332.
FT                                {ECO:0000269|PubMed:23979357}.
FT   MUTAGEN     332    332       K->R: Reduces ubiquitination. Strongly
FT                                reduces ubiquitination; when associated
FT                                with R-326.
FT                                {ECO:0000269|PubMed:23979357}.
FT   CONFLICT    320    320       G -> R (in Ref. 1; CAB50866).
FT                                {ECO:0000305}.
SQ   SEQUENCE   369 AA;  38923 MW;  42B79047A9AD9837 CRC64;
     MGPGARRQGR IVQGRPEMCF CPPPTPLPPL RILTLGTHTP TPCSSPGSAA GTYPTMGSQA
     LPPGPMQTLI FFDMEATGLP FSQPKVTELC LLAVHRCALE SPPTSQGPPP TVPPPPRVVD
     KLSLCVAPGK ACSPAASEIT GLSTAVLAAH GRQCFDDNLA NLLLAFLRRQ PQPWCLVAHN
     GDRYDFPLLQ AELAMLGLTS ALDGAFCVDS ITALKALERA SSPSEHGPRK SYSLGSIYTR
     LYGQSPPDSH TAEGDVLALL SICQWRPQAL LRWVDAHARP FGTIRPMYGV TASARTKPRP
     SAVTTTAHLA TTRNTSPSLG ESRGTKDLPP VKDPGALSRE GLLAPLGLLA ILTLAVATLY
     GLSLATPGE
//
